drugset / Trial / NCT01718951

Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial

NCT01718951

Phase 4 Completed 30 enrolled Tuen Mun Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy of golimumab with pamidronate in the treatment of axial spondyloarthropathy

Timeline

Start
2012-08
Primary completion
2014-03
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Golimumab Monoclonal antibody 50 mg Subcutaneous
Comparator Pamidronate Small molecule 60 mg Intravenous

Indications